Prometheus Biosciences, Inc.
RXDXDelisted Jun 16, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001718852
Prometheus Biosciences, Inc. was delisted on Jun 16, 2023; its insiders filed their last Form 4 on Jun 16, 2023; 220 institutions reported holding it in 13F filings for Q1 2023, worth $4.35B in total; no superinvestor held it.
Q2 2021 vs. Q1 2021
How the institutions holding Prometheus Biosciences, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 41 | 49 | +8 |
| Shares | 24.2M | 24.2M | −72.1K (−0.3%) |
| Value | $425.7M | $585.6M | +$159.8M (+37.5%) |
New holders (22)
Institutions that held Prometheus Biosciences, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State Street Corp | 155,801 | $3.83M | 0.00% |
| Northern Trust Corp | 110,738 | $2.72M | 0.00% |
| Charles Schwab Investment Management Inc | 75,128 | $1.85M | 0.00% |
| Nuveen Asset Management, LLC | 32,373 | $795.0K | 0.00% |
| Bank of New York Mellon Corp | 31,404 | $771.0K | 0.00% |
| California State Teachers Retirement System | 15,614 | $383.0K | 0.00% |
| State of Wisconsin Investment Board | 14,700 | $361.0K | 0.00% |
| Rhumbline Advisers | 10,369 | $255.0K | 0.00% |
| Jump Financial, LLC | 10,311 | $253.0K | 0.02% |
| New York State Common Retirement Fund | 9,700 | $238.0K | 0.00% |
| Virtus ETF Advisers LLC | 9,519 | $234.0K | 0.10% |
| JPMorgan Chase & Co | 6,822 | $168.0K | 0.00% |
| Deutsche Bank AG | 6,709 | $165.0K | 0.00% |
| American International Group, Inc. | 6,333 | $156.0K | 0.00% |
| STRS Ohio | 2,600 | $63.0K | 0.00% |
| Tower Research Capital LLC (TRC) | 999 | $25.0K | 0.00% |
| Legal & General Group Plc | 902 | $22.0K | 0.00% |
| Ameritas Investment Partners, Inc. | 886 | $22.0K | 0.00% |
| Royal Bank of Canada | 773 | $19.0K | 0.00% |
| Citigroup Inc | 537 | $13.0K | 0.00% |
| Panagora Asset Management Inc | 245 | $6.00K | 0.00% |
| Wells Fargo & Company | 73 | $2.00K | 0.00% |
Sold out (14)
Institutions that held Prometheus Biosciences, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
| Institution | Shares, Q1 2021 | Value, Q1 2021 |
|---|---|---|
| Price T Rowe Associates Inc | 525,000 | $9.59M |
| Great Point Partners LLC | 250,000 | $4.57M |
| Millennium Management LLC | 186,157 | $3.40M |
| Wellington Management Group LLP | 150,193 | $2.74M |
| Marshall Wace North America L.P. | 79,171 | $1.45M |
| Goldman Sachs Group Inc | 59,083 | $1.08M |
| Alyeska Investment Group, L.P. | 50,000 | $913.0K |
| TD Asset Management Inc | 34,465 | $629.0K |
| Pinz Capital Management, LP | 31,300 | $572.0K |
| Caas Capital Management LP | 15,000 | $274.0K |
| Silverarc Capital Management, LLC | 15,000 | $274.0K |
| Hound Partners, LLC | 10,292 | $188.0K |
| Maven Securities LTD | 8,333 | $152.0K |
| UBS Group AG | 776 | $14.0K |